“What’s the secondary liver cancer?”
Remedial liver cancer, also known as transferive liver cancer, is a more common and complex situation in cancer treatment. Unlike primary liver cancer, tumour cells do not originate in the liver itself, but in other parts of the body.
In the physical structure of the human body, the blood circulation and lymphocyte system are like a cross-crossing traffic network. When cancer occurs in an organ of the body, the cancer cell can use these “channels” to leave the original hair, swim to the liver and stay, grow and reproduce within the liver. These cancer cells form new tumours in the liver, which is secondary liver cancer. For example, common clitoris cancer, which can be transported to the liver through the door vein system, and breast cancer cells may be transferred to it through lymph or blood circulation.
Symptoms of secondary liver cancer are mixed. Early diagnosis may be difficult because there may be no visible symptoms or only some non-specific manifestations, such as lack of strength and reduced appetite. As the condition progresses, the patient may suffer from liver pain, which may be persistent blunt pain or swelling. Large liver swelling is also one of the common symptoms, and the upper right abdomen can be touched during medical examination. If tumours oppress the cholesterol, they may also lead to yellow stings, in the form of yellowing of skin and membranes. In addition, late-stage patients may suffer from abdominal water, abdominal swelling and abdominal insufficiency. In terms of pathological characteristics, the tumour pattern and nature of secondary liver cancer is closely related to the original tumour. The tumour may grow faster and become more invasive if the primary tumour is of a high degree of malignity and is transferred to the liver. The distribution of transfer stoves within the liver also varies, ranging from isolated knots to multiple knots, and can even spread over the whole liver.
In the area of diagnosis, there are various methods of medicine. Visual examinations play a key role, and ultrasound examinations can detect endemic pathologies in the liver, but there may be some limitations to smaller stoves. The CT scan provides a clearer picture of the tumour ‘ s size, location, number and relation to the surrounding tissue and enhances the CT ‘ s ability to observe the tumour ‘ s blood flow. MRI has a high resolution of soft tissues and is important for identifying diagnosis. In addition, tumour markers from blood tests are also useful for diagnosis, although regenerative liver cancer from different primary tumour sources may vary, such as the possibility of an increase in the antigen of cancer (CEA) during the transfer of liver from colon cancer.
The treatment of regenerative liver cancer is a complex multidisciplinary and integrated treatment process. In the case of single-shot transfer stoves and effective control of primary tumours, surgery to remove liver transfer stoves is a viable option. Local treatments such as radio-frequency digestion, microwave digestion and catheter artery pulsation (TACE) may also be considered for patients who cannot be operated. These methods can, to some extent, control the growth of tumours and mitigate symptoms. At the same time, full-body treatment, such as chemotherapy, target treatment and immunotherapy, also plays an important role in the treatment of secondary liver cancer. Chemotherapy can kill cancer cells, but can also cause some damage to normal cells. Target treatment is targeted at specific targets for cancer cells, with higher accuracy and relatively small side effects. Immunization treatments combat cancer cells by activation of the human body ‘ s own immune system.
Remedial liver cancer is a serious threat to the life and well-being of patients, and understanding of its mechanisms, symptoms, diagnostics and treatments is crucial to improving the survival and quality of life of patients. Early detection, accurate diagnosis and reasonable treatment are key to addressing secondary liver cancer.
Hepatic cancer, regenerative liver cancer.
